Drugs / SERDEMETAN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00676910 | Nov 2006 → Feb 2010 | neoplasm | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SERDEMETAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL2137530 ↗ |
| Known as | JNJ-26854165 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00676910 ↗ |
| Modality | Small molecule | — CHEMBL2137530 ↗ |
| Route | Oral | “The drug will be taken by mouth every day in each 21-day cycle.” NCT00676910 ↗ |